The panel, co-moderated by Joshua Vieth, Ph.D., Senior Director of Research at Breakthrough T1D, and Ulf Hannelius, Ph.D., MBA, CEO of Diamyd Medical, brought together leading clinicians and patient advocates, including Stephen Karpen, Pharm.D. (Breakthrough T1D), Laura Jacobsen, M.D. (University of Florida), Emily Sims, M.D. (Indiana University), Jason Gaglia, M.D. (Harvard University), and Alecia Wesner, a person with Type 1 Diabetes, and clinical trial education advocate. The panel discussion underscored the critical role of precision medicine in shaping the future of disease-modifying therapies for Type 1 Diabetes.

A recurring theme of the panel was the need to tailor both clinical trials and clinical conversations to the individual biology and lived experiences. The panel also tackled structural changes needed for real-world implementation once therapies are approved as well as recruitment challenges, especially for trials targeting subsets of the Type 1 Diabetes population. Looking ahead, panelists called for training programs, policy advocacy, and equitable outreach to underserved populations.

"The panel made it clear: precision medicine in type 1 diabetes isn't just about matching therapies to biology-it's about tailoring the entire clinical and scientific experience to the individual", says Ulf Hannelius, CEO of Diamyd Medical.

For the full panel discussion, see: https://www.youtube.com/watch?v=EZmeDnKEffk

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd^® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd^® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd^® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial with potential for an accelerated approval pathway in the US is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group - both in a largescale meta-analysis as well as in the Company's prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.